Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Endocrine ; 82(2): 406-413, 2023 11.
Artículo en Inglés | MEDLINE | ID: mdl-37488407

RESUMEN

BACKGROUND AND OBJECTIVE: Adrenal incidentalomas (AIs) are lesions larger than 1 cm that are incidentally detected in the adrenal glands. Chest computed tomography (CCT) is widely used in the first evaluation of patients with suspected coronavirus disease (COVID-19) that resulted in many incidental findings in the thorax and upper abdomen. In this study, we aimed to investigate the frequency of AI and their effects on the course and outcome of COVID-19 regardless of functional status. MATERIAL AND METHODS: We included 2493 patients aged between 18 and 99 years and whose adrenal glands were clearly visible in CCT images. They were divided into two groups: those with AI (AI group) and without AI (Control group). RESULTS: AI was detected in 148 (5.93%) patients and 80 (54.1%) of them were male. There was no difference in sex distribution between the groups, but the median age of patients with AI was significantly higher than those without AI [54.5 (20-94 years) vs. 42 (18-99 years); p < 0.001)]. In addition, in the AI group, both hospitalizations due to COVID-19-related conditions (30.4 vs. 21.2%, p = 0.008) and the mortality rate experienced during this time was significantly higher (14.7 vs. 7%, p < 0.001) diseases. The AI group had a significantly higher comorbidity rate than the control group (61.5 vs. 41.9%, p < 0.001). The most common comorbid diseases were hypertension, cardiovascular diseases, diabetes mellitus, respiratory system diseases, and hyperlipidaemia. Advanced age and male gender in terms of mortality, advanced age and covid 19 positivity in terms of hospitalization were determined as significant risk factors. CONCLUSIONS: The presence of AI may increase the morbidity and mortality rates associated with COVID-19, regardless of their functional status. Therefore, patients subjected to CCT imaging for COVID-19-related lung diseases should also be evaluated for AI. Careful follow-up of patients with COVID-19 and AI is necessary to monitor the progression of COVID-19.


Asunto(s)
Neoplasias de las Glándulas Suprarrenales , COVID-19 , Diabetes Mellitus , Humanos , Masculino , Adolescente , Adulto Joven , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Femenino , Neoplasias de las Glándulas Suprarrenales/complicaciones , Neoplasias de las Glándulas Suprarrenales/diagnóstico por imagen , Neoplasias de las Glándulas Suprarrenales/patología , Hallazgos Incidentales , COVID-19/complicaciones
2.
Hormones (Athens) ; 20(2): 259-268, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33730355

RESUMEN

The novel SARS-CoV-2 has spread to virtually all countries of the world infecting millions of people, the medical burden of this disease obviously being enormous. The gonads of both sexes are among the organs that may be affected by COVID-19 and/or may affect the severity of the disease. The clinical spectrum of SARS-CoV-2 infection clearly differs between genders. The current evidence indicates that the underlying mechanism of such an interaction could be associated with genetic, hormonal, and immunological differences, as well as with gender differences in such habits as smoking and alcohol use. On the other hand, there are controversies as to how and to what extent the gonads could be affected by COVID-19, possibly impacting upon sex steroids, fertility, and other functions. This review underlines the possible mechanisms that could clarify these questions concerning COVID-19 and the gonads. In addition, reference is made to potential new treatment modalities presently under investigation, these supported by accumulating data published in the recent literature.


Asunto(s)
COVID-19/epidemiología , Trastornos Gonadales/etiología , Gónadas , Pandemias , SARS-CoV-2 , COVID-19/complicaciones , Femenino , Salud Global , Trastornos Gonadales/epidemiología , Humanos , Incidencia , Masculino , Factores Sexuales
3.
Obes Surg ; 29(12): 3948-3953, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31290109

RESUMEN

BACKGROUND: There are many factors that affect weight loss after bariatric surgery. The present study evaluated the impact of health literacy on weight loss after bariatric surgery in morbidly obese patients. METHODS: The data of 118 patients who underwent laparoscopic sleeve gastrectomy for morbid obesity (body mass index-BMI ≥ 40 kg/m2) and completed a 1-year follow-up period were recorded and evaluated, prospectively. The Turkish version of the 47-item European Health Literacy Survey Questionnaire (HLS-EU-Q47) was used to evaluate the health literacy of these patients. Their demographic characteristics, preoperative and postoperative weight (at 6 and 12 months), BMI, the percentage of excess weight loss (% EWL), excess BMI loss (% EBL) and total weight loss (%TWL), comorbidities, socioeconomic characteristics (marital status, income level, educational status, and duration), and HLS-EU-Q47 results were recorded and compared. RESULTS: A significant inverse relationship was identified between preoperative BMI and scores for health promotion health literacy and general health literacy indexes (p = 0.024 and p = 0.032, respectively). A significant positive relationship was noted between % EWL and % EBL at 6 and 12 months, and health promotion health literacy index scores (6 months: p = 0.004, p = 0.006; 12 months: p < 0.001 and p < 0.001, respectively). A similar significant positive relationship was recorded between the % EWL and % EBL at 12 months and the health care health literacy index scores (p = 0.042 and p = 0.036, respectively). There was also a significant positive relationship between general health literacy index scores and % EWL and % EBL at 12 months (p = 0.022 and p = 0.021, respectively). % EWL at 12 months increased by 0.39, with a 1-point increase in health promotion and health literacy index scores. CONCLUSIONS: A high health literacy index score in morbidly obese patients is associated with successful weight loss after bariatric surgery.


Asunto(s)
Gastrectomía , Alfabetización en Salud/estadística & datos numéricos , Obesidad Mórbida/cirugía , Pérdida de Peso , Adolescente , Adulto , Femenino , Estudios de Seguimiento , Gastrectomía/métodos , Humanos , Laparoscopía , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Resultado del Tratamiento , Adulto Joven
4.
Metab Syndr Relat Disord ; 17(3): 167-172, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30688550

RESUMEN

BACKGROUND: We investigated the effect of short-term telmisartan usage in addition to lifestyle changes such as diet and exercise on insulin resistance, lipid metabolism, and serum adiponectin and tumor necrosis factor-alpha (TNF-α) levels in hypertensive patients with metabolic syndrome (MetS). METHODS: A total of 36 hypertensive patients with MetS were randomized to telmisartan and control groups in an open-labeled prospective study. RESULTS: There were significant decreases in anthropometric variables of patients according to baseline measurements in both groups at the end of the study. Serum insulin level and insulin resistance assessed by homeostasis model assessment-insulin resistance were decreased significantly in the telmisartan group (P = 0.040 and P = 0.034, respectively) compared with the controls, while there was no statistically significant change in the lipid profiles of the two groups. Serum adiponectin level was increased by 19.1% ± 41.7% in the telmisartan group, but intergroup analysis revealed no significant change. There was also no significant change in serum TNF-α level in either group. CONCLUSION: It has been observed that even short-term telmisartan treatment had favorable effects on insulin resistance and glucose metabolism compared with lifestyle changes alone. The fundamental effect of telmisartan treatment on insulin resistance renders it a good therapeutic option for hypertensive patients with MetS.


Asunto(s)
Adiponectina/sangre , Hipertensión/tratamiento farmacológico , Resistencia a la Insulina , Síndrome Metabólico/tratamiento farmacológico , Telmisartán/administración & dosificación , Factor de Necrosis Tumoral alfa/sangre , Adolescente , Adulto , Anciano , Antihipertensivos/administración & dosificación , Antihipertensivos/efectos adversos , Esquema de Medicación , Femenino , Humanos , Hipertensión/sangre , Hipertensión/complicaciones , Masculino , Síndrome Metabólico/sangre , Síndrome Metabólico/complicaciones , Persona de Mediana Edad , Telmisartán/efectos adversos , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven
5.
J Diabetes Res ; 2016: 1309502, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26998491

RESUMEN

AIM: To investigate the effect of exenatide treatment on serum ghrelin levels in obese female patients with type 2 diabetes mellitus. METHODS: Fourteen female patients with type 2 diabetes mellitus being treated with metformin and exenatide were enrolled. A mixed meal test was applied to the patients while continuing with their daily medications. Blood samples were taken before and at 60, 120, and 180 minutes following mixed meal test to measure serum total ghrelin, glucose, and insulin levels. The following week, exenatide treatment of the patients was paused for 24 hours and the same experimental procedures were repeated. RESULTS: Serum ghrelin levels were suppressed significantly at 180 minutes with exenatide treatment compared with baseline (294.4 ± 57.5 versus 234.5 ± 59.4 pg/mL) (p < 0.001). Serum ghrelin levels at 180 minutes were statistically different when percentage change in serum ghrelin levels after mixed meal tests with and without exenatide usage were compared (p = 0.001). Estimated total area under the curve values for serum ghrelin concentrations was also significantly lower with exenatide compared with omitted treatment (p = 0.035). CONCLUSION: These results suggest that the effect of exenatide on weight loss may be related with the suppression of serum ghrelin levels, which is an orexigenic peptide.


Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Ingestión de Alimentos , Ghrelina/sangre , Hipoglucemiantes/uso terapéutico , Incretinas/uso terapéutico , Obesidad/complicaciones , Péptidos/uso terapéutico , Periodo Posprandial , Ponzoñas/uso terapéutico , Adulto , Biomarcadores/sangre , Estudios Transversales , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/líquido cefalorraquídeo , Diabetes Mellitus Tipo 2/complicaciones , Regulación hacia Abajo , Quimioterapia Combinada , Exenatida , Femenino , Humanos , Metformina/uso terapéutico , Persona de Mediana Edad , Obesidad/sangre , Obesidad/diagnóstico , Estudios Prospectivos , Factores de Tiempo , Resultado del Tratamiento , Pérdida de Peso/efectos de los fármacos
6.
J Diabetes Res ; 2015: 807891, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26273677

RESUMEN

AIM: To investigate the efficacy of combined therapy of insulin and rosiglitazone on metabolic and inflammatory parameters, insulin sensitivity, and adipocytokine levels in patients with type 1 diabetes mellitus (type 1 DM). MATERIAL AND METHODS: A total of 61 adults with type 1 DM were randomly and prospectively assigned in open-label fashion to take insulin and rosiglitazone 4 mg/day (n = 30) or insulin alone (n = 31) for a period of 18 weeks while undergoing insulin therapy without acute metabolic complications. RESULTS: Combination therapy did not significantly improve metabolic and inflammatory parameters, insulin sensitivity, and adiponectin levels. While leptin and resistin levels decreased in both groups (group 1: resistin 6.96 ± 3.06 to 4.99 ± 2.64, P = 0.006; leptin 25.8 ± 17.6 to 20.1 ± 12.55, P = 0.006; group 2: resistin 7.16 ± 2.30 to 5.57 ± 2.48, P = 0.031; leptin 16.72 ± 16.1 to 14.0 ± 13.4, P = 0.007) Hgb and fibrinogen levels decreased only in group 1 (Hgb 13.72 ± 1.98 to 13.16 ± 1.98, P = 0.015, and fibrinogen 4.00 ± 1.08 to 3.46 ± 0.90, P = 0.002). Patients in both groups showed weight gain and the incidence of hypoglycemia was not lower. DISCUSSION: The diverse favorable effects of TZDs were not fully experienced in patients with type 1 DM. These results are suggesting that insulin sensitizing and anti-inflammatory characteristics of TZDs were likely to be more pronounced in patients who were not totally devoid of endogenous insulin secretion.


Asunto(s)
Adipoquinas/sangre , Diabetes Mellitus Tipo 1/sangre , Quimioterapia Combinada , Inflamación/tratamiento farmacológico , Insulina/administración & dosificación , Tiazolidinedionas/administración & dosificación , Adiponectina/metabolismo , Adulto , Anciano , Glucemia/metabolismo , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Ensayo de Inmunoadsorción Enzimática , Femenino , Fibrinógeno/metabolismo , Humanos , Hiperglucemia/sangre , Hipoglucemiantes/uso terapéutico , Insulina/metabolismo , Secreción de Insulina , Leptina/sangre , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Resistina/sangre , Rosiglitazona , Adulto Joven
7.
J Clin Endocrinol Metab ; 99(10): E2067-75, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25033069

RESUMEN

CONTEXT: Gordon Holmes syndrome (GHS) is characterized by cerebellar ataxia/atrophy and normosmic hypogonadotropic hypogonadism (nHH). The underlying pathophysiology of this combined neurodegeneration and nHH remains unknown. OBJECTIVE: We aimed to provide insight into the disease mechanism in GHS. METHODS: We studied a cohort of 6 multiplex families with GHS through autozygosity mapping and whole-exome sequencing. RESULTS: We identified 6 patients from 3 independent families carrying loss-of-function mutations in PNPLA6, which encodes neuropathy target esterase (NTE), a lysophospholipase that maintains intracellular phospholipid homeostasis by converting lysophosphatidylcholine to glycerophosphocholine. Wild-type PNPLA6, but not PNPLA6 bearing these mutations, rescued a well-established Drosophila neurodegenerative phenotype caused by the absence of sws, the fly ortholog of mammalian PNPLA6. Inhibition of NTE activity in the LßT2 gonadotrope cell line diminished LH response to GnRH by reducing GnRH-stimulated LH exocytosis, without affecting GnRH receptor signaling or LHß synthesis. CONCLUSION: These results suggest that NTE-dependent alteration of phospholipid homeostasis in GHS causes both neurodegeneration and impaired LH release from pituitary gonadotropes, leading to nHH.


Asunto(s)
Ataxia Cerebelosa/genética , Hormona Liberadora de Gonadotropina/deficiencia , Hipogonadismo/genética , Degeneración Nerviosa/genética , Fosfolipasas/genética , Pubertad Tardía/genética , Adolescente , Hidrolasas de Éster Carboxílico/genética , Hidrolasas de Éster Carboxílico/metabolismo , Ataxia Cerebelosa/metabolismo , Salud de la Familia , Femenino , Hormona Liberadora de Gonadotropina/genética , Hormona Liberadora de Gonadotropina/metabolismo , Homeostasis/genética , Humanos , Hipogonadismo/metabolismo , Masculino , Persona de Mediana Edad , Degeneración Nerviosa/metabolismo , Linaje , Fosfolipasas/metabolismo , Fosfolípidos/metabolismo , Pubertad Tardía/metabolismo
8.
Nat Genet ; 41(3): 354-358, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19079066

RESUMEN

The timely secretion of gonadal sex steroids is essential for the initiation of puberty, the postpubertal maintenance of secondary sexual characteristics and the normal perinatal development of male external genitalia. Normal gonadal steroid production requires the actions of the pituitary-derived gonadotropins, luteinizing hormone and follicle-stimulating hormone. We report four human pedigrees with severe congenital gonadotropin deficiency and pubertal failure in which all affected individuals are homozygous for loss-of-function mutations in TAC3 (encoding Neurokinin B) or its receptor TACR3 (encoding NK3R). Neurokinin B, a member of the substance P-related tachykinin family, is known to be highly expressed in hypothalamic neurons that also express kisspeptin, a recently identified regulator of gonadotropin-releasing hormone secretion. These findings implicate Neurokinin B as a critical central regulator of human gonadal function and suggest new approaches to the pharmacological control of human reproduction and sex hormone-related diseases.


Asunto(s)
Hipogonadismo/genética , Neuroquinina B/genética , Neuroquinina B/fisiología , Receptores de Neuroquinina-3/genética , Reproducción/genética , Secuencia de Aminoácidos , Cromosomas Humanos Par 4 , Análisis Mutacional de ADN , Familia , Gónadas/metabolismo , Gónadas/fisiología , Humanos , Kisspeptinas , Modelos Biológicos , Mutación/fisiología , Neuroquinina B/metabolismo , Neuronas/metabolismo , Linaje , Receptores de Neuroquinina-3/metabolismo , Reproducción/fisiología , Homología de Secuencia de Aminoácido , Proteínas Supresoras de Tumor/metabolismo
10.
Diabetes Res Clin Pract ; 81(1): 56-60, 2008 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18358555

RESUMEN

The aim of the study was to evaluate the effect of metformin on markers of endothelial function, vascular inflammation and factors of thrombosis in obese type 2 diabetic patients. Twenty-four type 2 diabetic patients (15 female, 9 male) previously under medical nutrition treatment (MNT)+regular exercise programme (REP) without chronic micro or macrovascular complications with the mean age of 50.5+/-1.5 years, diabetes duration of 17.9+/-6.3 months and body mass index (BMI) of 31.7+/-0.8 kg/m(2) were enrolled in the study. In the first 4 weeks, all the patients continued MNT+REP. In the following 12 weeks, metformin (mean daily dosage of 1381+/-85 mg) was added. After the first period with MNT+REP, BMI, waist circumference, fat percentage, blood pressure and HDL cholesterol decreased significantly. After metformin addition, there was a significant decrement in BMI, waist circumference, fat percentage, fasting and postprandial plasma glucose, hemoglobin A1C, plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor (VEGF) and increment in beta cell reserve values of the patients. Our results indicated that, metformin addition had beneficial effect on VEGF and PAI-1 levels in obese type 2 diabetic patients under MNT+REP, independent from its' favourable effects on BMI and glycemic control.


Asunto(s)
Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Metformina/uso terapéutico , Obesidad/sangre , Inhibidor 1 de Activador Plasminogénico/sangre , Factor A de Crecimiento Endotelial Vascular/sangre , Adulto , Anciano , Glucemia/metabolismo , Índice de Masa Corporal , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/fisiopatología , Ejercicio Físico , Femenino , Humanos , Hipoglucemiantes/uso terapéutico , Lípidos/sangre , Masculino , Metaloproteinasa 9 de la Matriz/sangre , Persona de Mediana Edad , Obesidad/complicaciones , Obesidad/fisiopatología , Estudios Prospectivos , Relación Cintura-Cadera
11.
Tumori ; 93(3): 292-5, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17679467

RESUMEN

Metastases to the thyroid gland are rarely encountered in clinical practice. They may originate from various primary sites, mainly kidney, lung, breast, esophagus and uterus. Prostate cancer is one of the most frequent malignancies in men. It generally has a favorable course, and autopsy series have shown occult prostate cancer in many subjects, especially in aged males. However, prostate cancer sometimes exhibits an aggressive behavior and cases with a poor prognosis have been reported. Occasional reports of metastasis from prostate cancer to the thyroid gland have been documented. We describe the case of a 73-year-old patient presenting with thyroid metastasis from long-standing prostate cancer.


Asunto(s)
Adenocarcinoma/secundario , Neoplasias de la Próstata/patología , Neoplasias de la Tiroides/secundario , Adenocarcinoma/química , Adenocarcinoma/diagnóstico , Adenocarcinoma/ultraestructura , Anciano , Biomarcadores de Tumor/análisis , Biopsia con Aguja Fina , Humanos , Masculino , Proteínas de Neoplasias/análisis , Antígeno Prostático Específico/análisis , Neoplasias de la Tiroides/química , Neoplasias de la Tiroides/diagnóstico , Neoplasias de la Tiroides/ultraestructura
12.
Tuberk Toraks ; 54(1): 65-70, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16615021

RESUMEN

Amyloidosis is a syndrome characterized by the deposition of an insoluble proteinaceous material in the extracellular matrix of one or several organs. Respiratory tract involvement with amyloid is rare and deposition of lower respiratory tract has been recognized in a variety of situations with different presentations. Primary idiopathic amyloidosis may be a diagnostic problem because of its low incidence and its variable manifestations. We report herein a case with multiple myeloma presenting diffuse interstitial infiltration, in which pulmonary AL type amyloidosis was diagnosed through transbronchial lung biopsy.


Asunto(s)
Amiloidosis/diagnóstico , Enfermedades Pulmonares Intersticiales/diagnóstico , Mieloma Múltiple/diagnóstico , Amiloidosis/complicaciones , Amiloidosis/diagnóstico por imagen , Amiloidosis/patología , Biopsia , Broncoscopía , Tos/etiología , Diagnóstico Diferencial , Disnea/etiología , Hemoptisis/etiología , Humanos , Enfermedades Pulmonares Intersticiales/complicaciones , Enfermedades Pulmonares Intersticiales/diagnóstico por imagen , Enfermedades Pulmonares Intersticiales/patología , Masculino , Persona de Mediana Edad , Mieloma Múltiple/complicaciones , Mieloma Múltiple/diagnóstico por imagen , Mieloma Múltiple/patología , Tomografía Computarizada por Rayos X
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA